Analyst consensus rating
Exagen Analyst Rating: Strong Buy
XGN is rated Strong Buy by 7 analysts with a $9.86 target. As of 2026-08-30.
Direct answer
Exagen's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.86.
Forecast evidence checked August 30, 2026.
Get free Exagen email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.39
- Average price target
- $9.86
- High price target
- $12.00
- Low price target
- $9.00
- Low target gap
- +21.8%
- Target upside
- +33.4%
- High target gap
- +62.4%
- Target range width
- 40.6%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Exagen?
Exagen has a verified Strong Buy consensus. The same dataset has an average price target of $9.86.
How far are Exagen's low and high targets from the recorded price?
The low target implies +21.8%, while the high target implies +62.4%.
How many analysts are included in Exagen's consensus?
The verified consensus includes 7 analysts.
How is Exagen's target upside or downside calculated?
The average target of $9.86 is divided by the recorded price of $7.39, then one is subtracted to produce +33.4%. This does not guarantee a future return.
When was Exagen's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.